News

Seeking Alpha1y
Ascendis Pharma Presents New Data and Updated Results from Phase 1/2 IL-Believe Trial at ASCO 2024 - Seeking Alpha
COPENHAGEN, Denmark, June 03, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S reported new and updated results from its ongoing Phase 1/2 IL-Believe Trial of TransCon IL-2 β⁄γ in a poster ...
Ascendis to Share Its Latest Endocrinology Rare Disease Data at ENDO 2025
Ascendis Pharma A/S (Nasdaq: ASND) today announced two oral presentations at ENDO 2025, the annual meeting of the Endocrine Society being held July 12-15, 2025, in San Francisco. Dr. Aliya Khan will ...
Business Insider1y
Ascendis Pharma to Report Full Year 2023 Financial Results and Provide Business Update on February 7, 2024 - Markets Insider
COPENHAGEN, Denmark, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it will report full year 2023 financial results and provide a business update on Wednesday ...
Morningstar1d
Ascendis to Share Its Latest Endocrinology Rare Disease Data at ENDO 2025 - Morningstar
COPENHAGEN, Denmark, July 07, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced two oral presentations at ENDO 2025, the annual meeting of the Endocrine Society being ...
Yahoo Finance1d
Ascendis to Share Its Latest Endocrinology Rare Disease Data at ENDO 2025 - Yahoo Finance
COPENHAGEN, Denmark, July 07, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced two oral presentations at ENDO 2025, the annual meeting of the Endocrine Society being ...
manilatimes1d
Ascendis to Share Its Latest Endocrinology Rare Disease Data at ENDO 2025 - The Manila Times
COPENHAGEN, Denmark, July 07, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced two oral presentations at ENDO 2025, the annual meeting of the Endocrine Society being held ...